Nyrada Inc. (ASX:NYR) Announces Positive Preclinical Study Results for NYR-BI03
Cardioprotection Study Results
Nyrada Inc. (ASX:NYR) announced that its NYR-BI03 drug provides strong cardioprotection when administered as a short-duration intravenous infusion following a myocardial infarction. The preclinical study demonstrated significant reductions in heart muscle injury size and Troponin I levels. Additionally, treated animals showed a decreased incidence of ventricular arrhythmias (VF events were completely suppressed in the 9 mg/kg treated group, with five events observed in the vehicle group), the leading cause of sudden cardiac death post-heart attack.
Phase I Clinical Trial
The company is conducting a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of NYR-BI03. This double-blind, randomised, placebo-controlled study involves five cohorts of eight healthy participants each. Final readouts are expected in the third quarter of 2025.
Executive Comments
CEO James Bonnar commented, “These findings are very exciting and further validate the strong cardioprotective efficacy of NYR-BI03, as demonstrated in our earlier study. It also confirms NYR-BI03’s anti-arrhythmic effects, as seen in a TRPC knockout animal model, validating our approach and highlighting the drug’s potential to address multiple risks following a heart attack.
“NYR-BI03 has now demonstrated preclinical efficacy in three significant indications, ischemic stroke, traumatic brain injury (TBI), and acute myocardial infarction, with our Phase I trial supporting multiple development pathways.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
